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The tumor promoter, 12-o-tetradecanoyl phorbol-l3-acetate (TPA)' has been
shown (1-6) to induce human resting T cellsfrom peripheral bloodto proliferate
in conjunction with mAbsspecific for T3, 9.3 (Tp44) andT11. In these activation
systems, monocytes or other necessary cells are not required. In particular, TPA
by itself can induce a low level of IL-2-R expression hours after activation. In
the presence of these mAbs, IL-2-R expression is markedly enhanced and IL-2
secretion is readily detectable .
To define further the requirements and cellular events for the induction of
resting T cells to proliferate, mAbs have been generated against Tcells activated
either by TPA or by an IgM anti-T3 antibody (7, 8). In this study, one ofthem
is shown to be reactive with a 28 kD/32 kD disulfide-linked and phosphorylated
dimer. TPA can readily induce T cells to express this antigen within one hour
of activation . Its expression precedes that of IL-2-R. Because of its rapid induc-
tion, this antigen has been termed early activation antigen 1 (EA 1).
Materials and Methods
Production of mAb EA 1.
￿
CFI mice were immunized intraperitoneally with 2 x 10' of
T cells activated with TPA for 12 h and with alum as an adjuvant. 3 wk later, 2 x 10'
TPA-activated T cells in PBS were injected intraperitoneally. Spleens were taken 3 d
later. Hybridomas were generated using myeloma cell line SP2/0 as a fusion partner as
previously described(1). Hybridomasupernatants were screened by flow cytometryagainst
T cellsand TPA-activated T cells, and those that reacted only TPA-activated T cells were
selected. The selected hybridomas were cloned twice on soft agar.
Antibody isotype was determined by ELISA with isotype-specific rabbit anti-mouse Ig
antisera (Meloy Laboratories Inc., Springfield, VA) and alkaline phosphatase-linked goat
anti-mouse Ig. mAb was purified from ascites using a goat anti-mouse Ig-Sepharose 4B
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column. Bound antibodies were eluted with glycine-HCI buffer, pH 2.9, dialyzed against
PBS, and sterilized by filtration.
Other mAbs used were mAb josh 524 (anti-HLA-DR, IgGI), mAb TE (anti-sheep
erythrocyte receptor, IgG2a), and mAb AT-1 (anti-IL-2-R, IgGl), as describedpreviously
(1, 9). mAb H4 (anti-platelet and monocyte, IgG2a) was equivalent to that described by
Burckhardt et al. (10) . B1, pan-B mAbwas obtained from Coulter Immunology (Hialeah,
FL). As control mAb, HDP-1 (anti-DNP, IgGl), SS1 (anti-sheep erythrocyte, IgG2a),
NS8.1 (anti-sheep erythrocyte, IgG2b), and NS4.1 (anti-sheep erythrocyte, IgM) were
used. Theseantibodies were generous gifts from Dr. J. Davie (Washington University, St.
Louis, MO).
Cell Preparation. PBMC were isolated from buffy coats or peripheral blood from
normal volunteers. T cells were obtained by SRBC rosetting (11) and were usually 95%
pure. These T cell preparations contained 1-2% monocytes. In certain experiments,
extensive depletion of monocytes was carried out by carbonyl-iron treatment, nylon-wool
column, and plastic adherence(1). Monocyte-free lymphocyte preparations were obtained
by counterflow centrifugal elutriation according to a modified procedure of Wahl et al.
(12). Monocytes were purified by Percoll continuous gradient centrifugation from PBMC
that were isolated from defibrinated blood (13). To minimize the attachment of platelets
to monocytes, monocytes were washed with PBS containing 0.5 mM EDTA. This mono-
cyte preparation was >90% pure, as determined by nonspecific esterase staining. Granu-
locytes were isolated from the peripheral blood, as thepellet fraction after Ficoll-Hypaque
densitygradient centrifugation. Contaminatingerythrocytes were removed by centrifuga-
tion on a 60, 65, and 70% Percoll discontinuous density gradient. The purity of the
granulocyte fraction was >95%, as determined by Wright-Giemsa staining. Platelets were
isolated from citrated platelet-rich plasma. The gated population of this platelet prepara-
tion was >95% pure, as shown by immunofluorescence staining with mAb H4. Erythro-
cytes were purified from the pellet fraction from peripheral blood after Ficoll-Hypaque
density gradient centrifugation. B cells were isolated from tonsils by the depletion of
SRBC rosetting cells (9). The resulting B cell preparation was >90% B1' and <1% TI 1+.
Immunofluorescence Studies.
￿
Cells were stained with mAb at 4°C for 30 min. After
extensive washing, the cells were further incubated with FITC-conjugated F(ab')2 goat
anti-mouse Ig antibodies at 4°C for 30 min. After further washings, the cells were
analyzed with an Epics V flow cytometer (Coulter Electronics Inc., Hialeah, FL) or a
Cytofluorograf Its (Ortho Diagnostic Systems Inc., Westwood, MA). Linear integrated
fluorescence of the gated population was measured and 10,000 cells were analyzed.
DNA and Protein SynthesisAssays.
￿
PBMC, T cells, or Bcells (2 X 105 cells) in 200 JAI of
complete medium were incubated in triplicate in flat-bottomed 96-well plates at 37'C for
3 d in a 5% C02 atmosphere. During the last 8 h, cells were pulsed with 0.4 ,Ci of ['H]
thymidine(spact, 75 Ci/mmol; Amersham Corp., ArlingtonHeights, IL)andincorporated
radioactivity was determined as described (1). To measure protein synthesis,
cells were incubated for 18 h in the same way and were labeled with 0.4 JCi of [5H]-
leucine (sp act, 128 Ci/mmol; Amersham Corp.) for the last 8 h.
For T cell activation, PHA (Difco Laboratories Inc., Detroit, MI), Con A (Pharmacia
Fine Chemicals, Piscataway, NJ), PWM, TPA (Sigma Chemical Co., St. Louis, MO),
tetanus toxoid (TT; State Laboratory Institute, Jamaica Plain, MA) and PPD (Connaught
Laboratories Limited, Willowdale, Canada) were used. The reagents we used for B cell
activation, were Immunobead rabbit anti-human IgM (Bio-Rad Laboratories, Richmond,
CA) and B cell growth factor (BCGF; Cellular Products Inc., Buffalo, NY). Cycloheximide
and Actinomycin D were from Sigma Chemical Co.
Immunoprecipitation and Autoradiography.
￿
TPA-activated T cellswere labeled with "-'I
(spe act, 15 .8 mCi/tLg of iodine; Amersham Corp.) by the lactoperoxidase technique, or
with [s5S]methionine (spe act, 1.150 Ci/mmol; Amersham Corp.) in methionine-free RPMI
1640 with dialyzed FCS. The labeled cells were solubilized in PBS containing 0.5% NP-
40 and 1 mM PMSF. When gels were run under nonreduced conditions, cells were
washed once with PBS containing 10 mM iodoacetamide and then were lysed with PBS
containing 0.5% NP-40, 1 mM PMSF, and 100 mM iodoacetamide. After centrifugation,1990
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supernatants were added to 30 kl of Sepharose 4B conjugated with goat anti-mouse Ig
antibodies (5 mg/ml) that had been incubated with mAbs. The mixture was incubated for
60 min at 4°C with constant mixing, and then was washed three times with a buffer
containing 10 mM Tris HCI (pH 7 .8), 0.6 M NaCl, 0.1 % SDS, and 0.05% NP-40 . The
absorbed proteins were released from the Sepharose by boiling the mixture for 3 min in
a sample buffer containing 0 .125 M Tris HCl (pH 6.8), 2% SDS, 5% 2-ME, and 10%
glycerol and were subjected to electrophoresis in 9 or 12% polyacrylamide gels in the
presence of 0.1 % SDS. Gels were stained, destained, and dried. For "S-labeled gels, gels
were stained and treated with 0.1 M sodium salicylate before drying. Autoradiography
was carried out against X-GMAT AR films at -70°C.
Phosphorylation reaction was performed as follows: T cells were washed three times
with a phosphate-free buffer (10 mM Hepes [pH 7.4], 140 mM NaCl, 5.4 mM KCI, 0.4
mM Ca(N03)2, 0.4 mM MgS04). Cells were suspended in phosphate-free RPMI 1640
with 10% dialyzed FCS at 5 x 106 cells/ml and were activated with 10 ng/ml of TPA for
18 h . Then 0 .1 MCi/ml of[32P]orthophosphate (carrier-free, Amersham Corp.) was added,
and incubation was continued for 3 h. The reactions were stopped with cold PBS
containing 10 mM sodium pyrophosphate, 50 mM NaF, and 2 mM EDTA and cells were
washed once more with this buffer. Immunoprecipitation and autoradiography were
carried out as described above, except that 5 mM sodium pyrophosphate, 2 mM EDTA,
and 50 mM NaF were added to the lysis buffer and washing buffers.
Results
Identification ofEA 1 as a Phosphorylated 28 kD/32 kD Disulfide-bonded Bimolec-
ular Complex. CFI mice were immunized with TPA-activated human T cells
and hybrrdomms were generated as described in Materials and Methods. The
supernatants were screened for their reactivities against TPA-activated and
resting T cells by indirect immunofluorescence. One hybridoma, termed EA 1,
was found to secrete antibodies reactive with TPA-activated T cells but not with
resting T cells. Hybridoma EA 1 was cloned twice on soft agar and mAb EA 1
was found to be an IgG2a molecule.
TPA-activated T cells were labeled with '251 by the lactoperoxidase method.
From the cell lysate, mAb EA 1 precipitated a protein of 60 kD molecular mass
as determined by SDS-PAGE under nonreducing conditions (Fig. 1, lane 1).
Upon reduction, two bands of 28 kD and 32 kD were resolved (Fig 1, lane 3).
To determine whether EA 1 was a phosphoprotein, 12P-labeled TPA-activated
T cells were lysed and immunoprecipitated with mAb EA 1 . As shown in lane S
of Fig. 1, both the 28-kD and 32-kD polypeptides were phosphorylated . Thus,
EA 1 is a phosphorylated 28 kD/32 kD disulfide-linked bimolecular complex.
Because of the similar molecular weights between EA 1 and HLA-DR, the
relationship between these two antigens was investigated further. Immunopre-
cipitates from 125I-labeled PHA-activated T cells by mAb EA 1 and mAb josh
524 (anti-HLA-DR) were electrophoresed in the same gel . The H chain of the
HLA-DR antigen migrated more slowly and both subunits of HLA-DR showed
sharper bands as compared with EA 1 . Furthermore, comparison of the V8
protease peptide-mapping patterns of EA 1 and HLA-DR molecules showed no
similarity. Thus, EA 1 and HLA-DR are not related.
Cell Distribution and Induction of EA 1 Expression.
￿
By flow cytometry, EA 1
was found on the majority of the cryopreserved thymocytes by indirect immu-
nofluorescence (Table I) . A small number of freshly isolated T and B cells wereHARA ET AL .
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FIGURE 1 .
￿
Immunoprecipitation ofEA 1 from '21 1 (lanes 1-4) and s2p (lanes 5and 6)-labeled
TPA-activated T cells . A 28/32 kD disulfide-linked complex was precipitated and both chains
were phosphorylated . T cells activated with 30 ng/mlofTPA for 18 h were labeled with 12-11
by lactoperoxidase : lanes 1 and 3 (mAb EA 1) and lanes 2 and 4 (control mAb) show
immunoprecipitation from 121I-labeled TPA-activated T cells, while lanes 5 (mAb EA 1) and
lane 6 (control mAb) show immunoprecipitation from s2P-labeled TPA-activatedT cells . Lanes
1 and 2 were run under nonreduced conditions and lanes3-6 were underreduced conditions.
weakly stained by mAb EA 1 . EA 1 was not detectable on monocytes, granulo-
cytes, erythrocytes, or platelets .
The expression of EA 1 byT cells was readily inducible as shown in Table 11 .
TPA induced the vast majority of the treated T cells to express EA 1 while
slightly more than half of the Con A- and PHA-activated T cells stained with
mAb EA 1 . In the case of PWM, a lesser T cell mitogen, only 16.5% of the
PWM-treated T cells expressed EA 1 . In an additional experiment, PHA and
Con A induced higher percentages of T cells to express EA 1 . In the case of
soluble antigen and alloantigen stimulation, ^-20% of the T cells were induced
to express EA 1 . Experiments were also carried out with T cell populations
depleted of monocytes . TPA inductionofEA 1 expression was readily detectable .
Although mAbEA 1 was generated against TPA-treatedT cells, it was readily1992 PHOSPHORYLATED 28 kD/32 kD EARLY ACTIVATION ANTIGEN
TABLE I
EA 1 Was Detectable in a Major Population of Thymocytes and
Weakly Expressed by a SmallNumber ofCirculating B and T Cells
* Thepercentages ofpositive cells were determined by flow cytometryby
counting 10,000 cells. Data were presented as mean ± SD from six
individuals.
TABLE II
Activated Tand B Cells Expressed EA 1
T Cells
B Cells
* Peripheral blood T cells(I06/ml) were stimulated with TPA (30ng/ml).
PHA (10tug/ml), Con A(5,ug/ml), or PWM(0.1 %) for 3 d, or with PPD
(5 pug/ml), TT (40 ug/ml), or irradiated allogeneic cells (2 X 105) for 6
d. Tonsillar B cells (106/ml) were stimulated with TPA (30 ng/ml) or
anti-IgM beads (500 t+g/ml)plus BCGF (5%) for 3 d. Both T andB cell
preparations containedasmall number of monocytes.
$ Percentages of positive cells were determined in a flow cytometer by
counting 10,000 cells. Data were presented as mean and f SD from six
individuals.
apparent that its expression was not limited to the T cell lineage. As shown in
Table II, TPA induced a majority of the isolated B cells to express EA 1. Anti-
A antibodies in the presence of crude BCGF were also shown to be potent
inducers.
Repeated attempts to induce EA 1 expression by monocytes and granulocytes,
as well as by fibroblasts, with TPA were unsuccessful. However, nonlymphoid
hematopoietic leukemia cell lines were shown to be responsive to TPA in EA 1
induction (Table III). Most T leukemia cell lines were found to express low levels
ofEA 1. All six cell lines were found to be responsive to TPA by increased EA
1 staining. In the case of B cell lines, transformed by EBV, only one of the five
were stained by mAb EA 1 without TPA treatment. Four of the five were
Stimulating agents* Percent positive$
Medium 1.0 ± 0.1
TPA 85.9 ± 13.9
PHA 56.5 ± 12.4
Con A 51 .6 ± 11 .7
PWM 16.5 ± 2.1
PPD 21 .5 ± 3.8
TT 17.1 ± 1.4
MLR 21 .1 ± 1.3
Medium 5.0 ± 3.7
TPA 89.3 t 16.8
Anti IgM + BCGF 58.1 ± 14
Cell type Percent positive*
Thymocytes 61 .3 ± 11 .4
T 7.1 ± 1 .3
B 6.6 ± 5.8
Monocytes <1
Granulocytes <1
Platelets <1HARA ET AL.
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TABLE III
EA I Expression by Hematopoietic Cell Lines: TPA-Inducedor
-Enhanced EA I Expression
Cell line
TPA
Absent Present
T Cell Lines
8042
￿
- ++++*
Jurkat
￿
++ ++++
MT-1
￿
++ ++++
CEM
￿
+ ++++
HSB-2
￿
+ ++++
Molt-4
￿
+ ++++
B Cell Lines
32AI
￿
-
￿
+
Daudi
￿
- +++
Raji
￿
-
￿
+
SeD
￿
+ +++
Josh 7
￿
-
￿
-
Non-lymphoid Lines
ML1
￿
+
￿
+
KGI
￿
- ++
HL60 -
￿
-
K562
￿
- +++
HEL
￿
++ +++
U937
￿
+ ++++
* -, <5%; +, 5-15%; ++, 15-50%; +++, 50-75%; ++++, >75%. The
reactivity of the cell lines were determined by indirect immunofluores-
cence with a flow cytometer. Threedeterminations were done with each
cell line.
responsive and a pre-B cell line,josh 7 (14), was not inducible. In six nonlymph-
oid cell lines, four were found to be responsive to TPA by an increase of EA 1
expression . These results indicate the need to explore further the possibility that
nonlymphoid hematopoietic cells can express EA 1 .
Kinetics of EA I Expression.
￿
The induction of EA 1 expression by T cells with
TPA was studied further. As shown in Fig. 2, EA 1 induction by TPA was dose
dependent. With as little as 0.3 ng/ml of TPA, a majority of T cells were induced
to express EA 1 . Full effect was seen with 1 ng/ml of TPA.
The induction of EA I expression by T cells with TPA was very rapid, as
shown in Fig. 3A. Although not shown, as early as 30 min after the addition of
TPA, a substantial number of T cells were stained by mAb EA 1 . In one rare
instance, EA 1 expression was seen in 15 min . After 1 h of activation, a vast
majority (85-90%) of the T cells were positive. The maximal percentage of T
cells expressing EA 1 was detected after 3-4 h . There was a slight increase in
the fluorescence intensity until 18-24 hours. After this period, both the per-
centage of EA I' T cells and the intensity of staining decreased gradually. For
comparison, TPA-induced EA 1 expression by B cells had less rapid kinetics, as
shown in Figure 3B.1994
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FIGURE 2.
￿
EA 1 induction by TPA is dose dependent. Isolated T cells were treated with
increasing doses of TPA for 4 h and EA I expression was measured by indirect immunofluo-
rescence. (A) Control without TPA; (B) 0.1 ng/ml; (C) 0.3 ng/ml; (D) 1 ng/ml ; (E) 5 ng/ml;
(F) 30 ng/ml.
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FIGURE 3.
￿
Cytofluorographic profiles of the kinetics of EA 1 expression. T cells (A) and B
cells (B) activated with TPA (30 ng/ml) were taken at the indicated times and stained with
mAb EA 1, followed by flow cytometer analysis. This is representative of four independent
experiments.
To minimize the possibility that resting T cells are partially activated by
rosetting with SRBC, a lymphocyte fraction was isolated by counterflow centrif-
ugal elutriation at 2,000 rpm with a flow rate of 12 ml/min . This fraction was
devoid of monocytes, as determined by esterase staining and surface marker
analysis. It stained 92% for T11 . TPA activation ofthis lymphocyte preparation
did not induce EA 1 expression at 30 min. However, 85% of the lymphocytes
were stained by mAb EA 1 after 1 h and the maximal number of EA 1+ T cells
was seen at 3 h. An additional experiment yielded similar results.
EA 1 Expression Preceded that ofIL-2-R.
￿
We compared the kinetics of expres-
sion of EA 1 and selected activation antigens on activated T and B cells (Fig. 4).
In the case of TPA-induced T cell activation, as shown in Fig. 4A, >85% of T
cells were positive for EA 1 within 1 h. By 4 h, >95% were positive. The
expression of IL-2-R was clearly delayed in comparison with that of EA 1. In
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￿
Kinetics of expression of EA 1 and selected activation antigens on activated T
and B cells. EA 1 expression preceded that of IL-2-R. A summary of four activation experi-
ments is shown: (A) EA 1, IL-2-R and HLA-DR on T cells activated with TPA (30 ng/ml);
and (B) EA 1 and IL-2-R on Bcellsactivatedwith TPA (30 ng/ml). 10,000 cells were analyzed
with a flow cytometer. (-0-) EA 1, (--0--) IL-2-R, (-~--) HLA-DR.
this system, HLA-DR was not induced significantly by 72 h. In the case of B
cells, TPA-induced EA 1 expression was less rapid, and 18-36 h were required
for its maximal expression (Fig. 4B). However, it is apparent that in the B cells,
EA 1 expression also preceded that of IL-2-R.
The earlier expression of EA 1 in comparison with IL-2-R expression was also
documented by biosynthetic labeling experiments. EA 1 was readily precipitated
by mAb EA 1 from T cells treated with TPA and labeled with [35S]methionine
for 4 h (Fig. 5, lane 5). In contrast, mAb AT-1 (9), reactive with the IL-2-R,
failed to precipitate any 35S-labeled peptide (Fig. 5, lane 6). Both antibodies did
not precipitate 35S-labeled peptides from unstimulated T cells (Fig. 6, lanes 2
and 3).
In addition to TPA, polyclonal mitogen stimulation of T cells also induced EA
1 earlier than IL-2-R expression (Table IV). By 4 h, EA 1 expression was readily
detectable. In another experiment, PHA induced 78.8, 94 .0, and 56.5% of EA
1+ cells at 4 h, 18 h, and 72 h, respectively. Similarly, 68 .5, 69 .8, and 51 .6% of
EA 1+ cells appeared after 4 h, 18 h, and 72 h, of activation with Con A,
respectively. Although EA 1 expression was readily detectable on T cells stimu-
lated by soluble antigens and alloantigens, its expression was not clearly shown
to precede that of IL-2-R. Studies at more time points between 84 and 108 h
would yield more definitive results.
Both Cycloheximide and Actinomycin D Inhibited EA 1 Expression.
￿
Because of
the rapid appearance of EA 1, the possibility that EA 1 was not newly synthesized
wasconsidered and ruled out. As shown in Fig. 6, cycloheximide inhibited EA I
expression in a dose-dependent manner. In both T and B cells, significant
inhibition of EA 1 expression was seen at 50,uM of cycloheximide. At 500 AM,
at which no leucine incorporation was detected, EA 1 expression was completely
inhibited. This inhibition was confirmed by experiments involving [35S]methio-
nine labeling and immunoprecipitation (Fig. 7).
EA 1 expression was further shown to require newly transcribed mRNA. At 11996
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FIGURE 5.
￿
EA 1 synthesis preceded that IL-2-R . T cells (10'/ml) labeled with ["Slmethionine
for 4 h in the absence (A) or presence (B) of 30 ng/ml of TPA . Lanes 1 and 4, control mAb ;
lanes2and 5,mAbEA 1 ; lanes3and 6, anti-IL-2-RmAbAT 1 undernonreducing conditions .
pg/ml, actinomycin D significantly inhibited EA 1 expression, as shown in Fig.
8C . When TPAand actinomycin D wereadded simultaneously, even at 10 Ag/ml
of the RNA synthesis inhibitor, a low level of EA 1 expression was seen, with a
small shoulder in the histogram (Figure 8E). Complete inhibition was seen when
the T cells were pretreated for 15 min before the addition ofTPA (Fig . 8F).
Although measurements were made at 4 h after the addition of TPA in the
presented experiments, similar results were obtained when EA 1 expression was
determined 1 h afterTPA activation .
mAb EA 1 Did Not Block T or B Cell Proliferation .
￿
To investigate whether or
not mAb EA 1 has any effect on T cell or B cell proliferation, mAb EA 1 was
purified from ascites by Sepharose 413 coupled with goat anti-mouse Ig . Asd
E
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FIGURE 6.
￿
EA 1 expression by T cells activated with TPA is inhibited by cycloheximide, a
protein synthesis inhibitor. T cells (A) and B cells (B) were treated with increasing doses of
cycloheximide, and EA 1 expression with measured by indirect immunofluorescence.
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TABLE IV
Kinetics ofEA 1 Expression by T Cells Activated by Mitogens, Soluble Antigens or Alloantigens
* See Table II.
$ The percentages of positive cells were determined by indirect fluorescence with mAb EA 1 and a
flow cytometer. <5% ofmitogen-stimulated T cells stained weakly with control mAbof appropriate
isotypes. In the case of T cells in cultures with antigens (PPD, TT, and MLC), <2% were weakly
positive. These controls were done at all time points.
§ The averages of three experiments were presented.
not done.
shown in Table V, mAb EA 1 had no effect on T cell proliferation induced by
TPA or PHA. B cell proliferation induced by TPA or anti-IgM plus BCGF was
not inhibited either. In addition, no significant inhibition by mAb EA 1 in Con
A-, PPD-, or allogeneic cell-induced proliferation or in IL-2-dependent prolif-
eration of T blasts was detected. mAb EA 1 was not mitogenic for either PBMC
or T or B cells.
Stimulating agents*
4h 18h
Percentpositive cellsafter:*
60h 84h 108h 132h 156h 180h
Expression of Ea 1
PHA 28 .0 49.2 51.7
Con A 43 .6 55.4 40.3
PWM 9.1 12.5 15.7
PPD - - 3.6 3.8 15.7 16.8 21 .5 17.9
TT - - 1.5 0.8 11 .5 10.1 14.2 17.1
MLC - - 3.4 3.5 20.1 16.1 21 .1 17 .4
Expression of IL-2-R
PHA 1.3 15.7 28.9
Con A 1.4 38.1 28.8
PWM 1.3 9.6 10.9
PPD - - 3.7 4.1 11 .4 10.1 18.8 23 .5
TT - - 3.1 3.1 8.6 5.7 13.4 12 .4
MLC - - 4.9 3.7 13.4 13.7 25.8 28.91998
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FIGURE 7 .
￿
EA I synthesis by T cells activated with TPA is inhibited by cycloheximide . TPA
activated T cells were labeled with ["S)methionine in the absence of cycloheximide (lane 1)
and in the presence of 50 gM cycloheximide (lane 2) and 500 MM cycloheximide (lane 3) .
Discussion
Activation of human lymphocytes is associated with the expression of new
surface antigens . These antigens include IL-2-R (reviewed in reference 15),
transferrin receptor (16, 17), insulin receptor (18), vitamin B 12 receptor (19,
20), enzymes (21-24), HLA-DR (25), as well as functionally yet undetermined
molecules (26-38) . Among these, IL-2-R, transferrin receptor, 4F2, andTLISA 1
are early activation antigens . However, these are only marginally detectable
several hours after activation and their maximal version occurs 24-72 h after
activation . In this study, EA 1 has been shown to be different from thesereported
activation antigens by its molecular weight, cell distribution, and rapid induction
within 1 h of activation .
EA 1 is a 28 kD/32 kD disulfide-linked dimer . Its molecular mass is very
similar to that of HLA-DR . In addition to the presented data, TPA-activated T
cells have been shown not to stain with both mouse monoclonal and rabbit
heterologous antibodies specific for HLA-DR (data not shown) . HLA-DR is
readily detectable on resting B cells and monocytes, while EA 1 is not expressed
by these cells . This is conclusive evidence that EA 1 is not related to HLA-DR .
The 60 kD molecular mass of EA 1 under nonreducing conditions is also similarHARA ET AL.
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FIGURE 8.
￿
EA 1 expression by T cells activated with TPA requires mRNA transcription. T
cells were activated with TPA (30 ng/ml) in the presence of actinomycin D (Act D). EA 1
expression was measured 4 h after treatment. TPA and Act D were added at the same time
in experiments shown in C-E. (A) Control without TPA and Act D; (B) no Act D; (C) 1 jug/ml
Act D; (D) 5 hg/ml Act D; (E) 10 pg/ml Act D. (F) Pretreatment of T cells for 15 min with
10 jug/ml Act D before the addition of TPA completely blocked EA 1 expression.
to pp 56`'STR^, a murine lymphocyte-specific, protein-tyrosine kinase, initially
identified in the T cell lymphoma LSTRA (39). However, EA 1 is a biomolecular
complex, whereas pp 56t'sTRn is a single peptide. In addition, preliminary exper-
iments indicate that threonine and serine are primarily phosphorylated in EA 1.
Thus EA 1 is not likely to be analogous to
pp56LSTRn. Udey et al. (40, 41) have
studied early changes in protein synthesis in human T lymphocytes exposed to
mitogens with [35S]methionine labeling and two-dimensional gel electrophoresis.
A membrane protein with a molecularmass of 28 kD wasshown to be synthesized
rapidly upon activation. Whether or not this protein is identical to the smaller
subunit of EA 1 remains to be determined.
Although EA 1 is not easily detectable on peripheral blood lymphocytes, its
presence on thymocytes is readily shown. The thymocytes used in the reported
experiments were cryopreserved and recovered. In general, the surviving thy-
mocytes are the more immature cells. It is likely that EA 1 is expressed on
immature thymocytes and it disappears as these thymocytes mature further. In
situ analysis with thymic tissue sections and other T cell surface markers defining
various stages of T cell differentiation will provide supportive evidence for this
thesis.
The induction of EA 1 expression is not limited to T cells. B cells are readily
inducible although kinetics of EA 1 expression is slower. Repeated attempts to
induce monocytes and granulocytes to express EA 1 have not been successful .
However, the finding that nonlymphoid cell lines can express EA 1 suggests that
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TABLE V
mAb EA 1 Did Not Block TandB Cell Proliferation
* T cells (2 X 105) were stimulated with TPA (30 ng/ml) or PHA (10 Ag/ml).
B cells (2 X 105) were stimulated with TPA (30 ng/ml) or anti-IgM beads (500 jug/ml) plus 5%
BCGF. [5H]Thymidineincorporation wasmeasured after 3 d of incubation.Standard deviations of
each mean value were within 15%. Both T and Bcells had 1-2% monocytes.
4mAb EA 1 was notadded to these cultures.
EA 1 has a broader cell distribution. It would be of considerable interest to
determine that progenitor cells of nonlymphoid hematopoietic lineages consti-
tutively express EA 1. If this is not the case, the question whether EA 1 is
inducible needs to be entertained.
TPA-induced EA 1 expression by T cells appears to be in a dose-dependent
manner. It is independent of monocytes. This induction is readily demonstrable
on lymphocytes not treated with SRBC. The slight delay in EA 1 expression
would indicate that a degree of T cell activation is induced by rosetting with
SRBC. The degree of EA 1 induction by mitogens is more variable. This may
relate to the varying numbers of monocytes and accessory cells in the cell
preparations. Further studies with T cell preparations that are extensively
depleted of monocytes will provide conclusive evidence whether mitogen-in-
duced EA 1 expression is independent of monocytes.
The speed of EA 1 induction is surprisingly rapid. In both TPA and mitogen
systems, EA 1 induction precedes that of IL-2-R in both T and B cells. In TPA-
activated T cells, EA 1 expression is detectable within 30-60 min, a time interval
at which little IL-2 mRNA induction has been demonstrated (42, 43). The
complete inhibition of EA i expression by cycloheximide and actinomycin D
indicates that EA 1 expression requires new mRNA and protein synthesis. It also
provides evidence for the need of gene activation for EA 1 expression. The rapid
nature of EA 1 induction would make it a desirable model for the studies of
gene activation .
Accumulative evidence indicates that sequential gene activation occurs during
the induction of resting T cells to proliferate (1, 4-6, 15, 42-44) . Different
mAb wg/ml
TPA*
[5H]Thymidine
PHA*
incorporation
TPA$
(cpm)
Anti-IgM +
BCGFt
EA 1 0.0 25,932 64,951 20,842 11,209
0.1 25,259 64,220 19,041 10,914
0.3 23,926 61,308 19,195 11,049
1.0 23,332 61,215 19,608 11,932
3.0 21,687 60,896 20,985 10,717
10.0 19,899 61,374 19,599 10,655
SS 1 (IgG2a anti-SRBC) 0.1 23,563 61,592 21,322 11,943
0.3 24,105 63,455 21,971 10,110
1.0 24,800 61,422 22,225 11,382
3.0 22,946 62,571 19,099 12,175
10.0 21,205 60,333 21,632 11,299
Without mitogen¢ 392 962 205 183HARA ET AL.
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inductive stimuli are required for various gene activation. The signals involving
activation via the T3/Ti complex have been studied in some detail (reviewed in
reference 44). The increase in free cytoplasmic Ca21 concentration and the
activation of protein kinase C(pkC) are identified as early events leading to IL-2
synthesis and proliferation. The synergism between these two signals is demon-
strated. In using TPA as a probe, it is postulated that many ofthe TPA-induced
cellular effects may be explained by its ability to activate pkC (reviewed in
reference 45). This has been supported by the studies (reviewed in reference 46)
using synthetic diacylglycerols (DAG), which may serve as a more physiological
signal for pkC activation. Recently, we have shown (47) that both L-oleoyl-2-
acetylglycerol and 1,2-dioctanoylglycerol could induce EA 1 expression. In
addition, the protein kinase inhibitor H-7, the most potent pkC inhibitor (48)
inhibits EA 1 expression completely (Bjorndahl, J. M., L. K. L. Jung, and S. M.
Fu, manuscript in preparation). Anti-T3 antibodies are shown to induce a
marked increase in free cytoplasmic Ca". This stimulus does not induce EA 1
but providesa synergizing signal to DAG-induced EA 1 expression. These studies
provide further evidence for the role ofpkC activation in lymphocyte activation.
With the development ofa cDNA probe for EA 1, it will be possible to determine
whether anti-T3 antibodies exert their synergism by increasing the rate ofeither
mRNA or protein synthesis. Although DAG can replace TPA in EA 1 induction,
we have obtained data indicating that IL-2-R expression is not induced either by
DAG, alone, or in the presence of anti-T3 antibodies. Thus, the possibility that
TPA has additional physiological effects in addition to pkC activation needs to
be considered. These studies also provide evidence to identify EA 1 induction as
a distinct stage ofTcell activation .
The physiological signal for EA 1 induction and the function ofEA 1 remain
to be determined. Because of its molecular structure, it is not likely that EA 1
may serve as the IL-1-R (49). The inability of mAb EA 1 to block lymphocyte
proliferate is not sufficient to preclude EA 1 as a receptor for a yet-to-be-
identified growth factor or its role in cell-cell interaction. The availability of
mAbs to differing epitopes of EA 1 would be helpful in further experiments.
The rapid induction kinetics may facilitate the search for a physiological ligand
for EA 1 .
Summary
With human Tcells activated by 12-o-tetradecanoyl phorbol-I3-acetate (TPA)
as immunogen, an IgG2a mAb, early activation antigen 1 (EA 1), was generated
against a 60-kD protein with disulfide-linked 28-kD and 32-kD subunits. Both
subunits were phosphorylated. The antigen, EA 1, was readily detectedon ^-60%
ofisolated and cryopreserved thymocytes, as determined by indirect immunoflu-
orescence. A low level of EA 1 expression was detectable on 6-7% of blood
lymphocytes. TPA-activated T cells expressed EA 1 as early as 30 min after
activation. By 1 h, 85-90% of the T cells stained with mAb EA 1. By 3-4 h, the
expression ofEA 1 wasdetected in>95% ofthe T cells. Although thepercentages
ofEA 1+ Tcells did not change, the intensity ofstaining increased slightly. After
18-24 h, both the percentage of EA 1+ cells and the intensity of staining
decreased gradually. TPA-induced EA 1 expression was independent of mono-2002
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cytes. EA 1 expression was slightly delayed in T cells that were isolated without
the rosette selection and treated with TPA . Nevertheless, >85% of these T cells
expressed EA 1 within 1 h, and the maximal number of EA 1 + T cells was also
detected at 3-4 h. In T cell populations with 1-2% monocytes, about 50-90%
of the PHA- or Con A-activated T cells expressed EA 1 with a slower kinetics.
EA 1 expression preceded that of IL-2-R in these activation processes. Similarly,
T cells activated by soluble antigens (tetanus toxoid and PPD) and alloantigens
in MLR also expressed EA 1 after a longer incubation . ^-20% of the T cells
stained for EA 1 at day 6 . EA 1 expression was not limited to activated T cells.
B cells activated by TPA or anti-IgM antibody plus B cell growth factor expressed
EA 1 . The kinetics of EA 1 expression was markedly slower and the staining was
less intense. Repeated attempts to detect EA 1 on resting and TPA-activated
monocytes and granulocytes have not been successful. However, the detection
of EA 1 in nonlymphoid cell lines would indicate that EA 1 may have a broader
cell distribution . EA 1 expression was due to de novo synthesis, as the induction
of EA 1 was blocked by cycloheximide and actinomycin D . Thus, EA 1 is the
earliest activation antigen detectable to date, and it would serve as a useful
marker for early T cell activation . Although mAb EA 1 has been shown not to
block T or B cell proliferation, the possibility that EA 1 is a receptor for a yet-
to-be-defined growth factor or that it plays an important function in cellular
interaction needs further consideration.
ReceivedforPublication IS August 1986.
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